The Dow is now on the cusp of a new record, as investors look beyond the COVID-19 spike to a vaccine.
The Telecom Tower Market is poised to experience spend growth of more than USD 42 billion between 2020-2024 at a CAGR of over 14.09%
The Zeolite Market will grow by 4069.07 th MT during 2020-2024
vitafusion Gummy Vitamins announces their partnership with WhyHunger, increasing access to nutritious food options.
Global Low Light Level Imaging Sensors Market 2020-2024 The analyst has been monitoring the low light level imaging sensors market and it is poised to grow by $ 1. 1 bn during 2020-2024, progressing at a CAGR of 9% during the forecast period.New York, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Low Light Level Imaging Sensors Market 2020-2024" - https://www.reportlinker.com/p05048534/?utm_source=GNW Our reports on low light level imaging sensors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increased government investments in military devices and the rising adoption of night vision devices by the automotive industry. In addition, increased government investments in military devices is anticipated to boost the growth of the market as well. The low light level imaging sensors market analysis includes an end-user segment, application segment, and geographical landscapes. The low light level imaging sensors market is segmented as below: By End-user • Defense • Industrial • Security and surveillance By Application • Night vision devices • Cameras • Optic lights • Others By Geographical Landscapes • APAC • North America • Europe • South America • MEA This study identifies the growing demand for night vision devices to seize lawbreakers as one of the prime reasons driving the low light level imaging sensors market growth during the next few years. The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our low light level imaging sensors market covers the following areas: • Low light level imaging sensors market sizing • Low light level imaging sensors market forecast • Low light level imaging sensors market industry analysis Read the full report: https://www.reportlinker.com/p05048534/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
The "Label-Free Detection Technology Market Research Report: By Product Type, Technology, Application, End User - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
Company Announcement * Genmab will not advance the development of enapotamab vedotin * Data from expansion cohorts did not meet stringent criteria for proof-of-concept * Genmab to prioritize development of other innovative product candidatesCopenhagen, Denmark; November 24, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that it will not advance the development of enapotamab vedotin. While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers. Accordingly, the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.“We are committed to developing innovative antibody products for patients with cancer, however the data from the enapotamab vedotin expansion cohorts unfortunately does not support moving this product candidate forward. This decision will allow us to focus more of our resources and energy on other programs in our robust next-generation antibody therapeutics pipeline,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.About Enapotamab Vedotin Enapotamab vedotin is an AXL targeted Antibody-Drug Conjugate (ADC) in which the monoclonal antibody is conjugated to the antimitotic drug monomethyl auristatin E. AXL is a signaling molecule overexpressed in several hematologic and solid malignancies. In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response. Enapotamab vedotin is fully owned by Genmab and the drug linker technology used for enapotamab vedotin was licensed from Seagen Inc.About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX® (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta® (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA® (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra® (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. Contact: Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 609 524 0065; E: firstname.lastname@example.orgFor Investor Relations: Andrew Carlsen, Senior Director, Investor Relations T: +45 3377 9558; E: email@example.com This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and Kesimpta® are trademarks of Novartis AG or its affiliates. DARZALEX® and DARZALEX FASPRO™ are trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc. Company Announcement no. 49 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V Denmark Attachment * 241120_CA49_EnV Update
Check out our guide to the best Bose soundbar, speaker and headphones deals for Black Friday
U.S. electric vehicle maker Tesla is looking at expanding in Europe by entering the mass-market segment with a compact car, Chief Executive Elon Musk said on Tuesday. "Possibly in Europe it would make sense to do, I guess, a compact car, perhaps a hatchback or something like that," Musk told an European online conference on batteries hosted by the German government. "In the U.S., the cars tend to be bigger for personal taste reasons," he said.
DefenseStorm, the leading cloud-based cybersecurity and cybercompliance management provider to regional and community banks and credit unions, announced today that it has raised a $12M Series B round, bringing its total funding to $47M. Georgian, a fintech investing in high growth technology companies, led the round, with participation from TTV Capital.
What happened Shares of Kosmos Energy (NYSE: KOS) leaped 18% within the first few minutes of trading on Nov. 24. That follows a trend of late: The offshore exploration and production company's stock is higher by around 40% over the past five trading days including today's early advance.
The "Global Hearth Market with COVID-19 Impact Analysis by Fuel Type (Wood, Electricity, Gas, Pellet), Product (Fireplace, Insert, Stove), Placement, Design, Application, Fireplace Type, Vent Availability, Ignition Type, Material, and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
Evictions have been in the news a lot lately, especially with the moratoriums enacted in response to the coronavirus pandemic and the backlash from landlords nationwide. For years, a group of Minneapolis tenants in five buildings in the city's Corcoran neighborhood fought to revoke their landlord's rental license. Stephen Frenz, the landlord in question, had apparently ignored his tenants' numerous pleas for better living conditions, so those tenants banded together and pushed their city council to bar Frenz from collecting rent.
With $90 million in deposits and $18.25 million in new financing, HMBradley is making moves as the Los Angeles-based entrant into the challenger bank competition. LA is home to a growing community of financial services startups and HMBradley is quickly taking its place among the leaders with a novel twist on the banking business. The company offers up to 3% interest on its savings accounts, much higher than most banks these days, and it's that pitch that has won over consumers and investors alike, according to the company's co-founder and chief executive, Zach Bruhnke.
Global Ostomy Care Accessories Market 2020-2024 The analyst has been monitoring the ostomy care accessories market and it is poised to grow by $ 165. 81 mn during 2020-2024 progressing at a CAGR of 7% during the forecast period.New York, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Ostomy Care Accessories Market 2020-2024" - https://www.reportlinker.com/p05048547/?utm_source=GNW Our reports on ostomy care accessories market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in older population, growth in awareness programs and the rising number of skilled professionals. In addition, increase in older population is anticipated to boost the growth of the market as well. The ostomy care accessories market analysis includes the end-user segment and geographical landscapes. The ostomy care accessories market is segmented as below: By End-user • Home care settings • Healthcare settings By Geographical Landscapes • North America • Europe • APAC • South America • MEA This study identifies the increase in online sales as one of the prime reasons driving the ostomy care accessories market growth during the next few years. Also, an increase in the prevalence of GI diseases and a rise in medical tourism will lead to sizable demand in the market. The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our ostomy care accessories market covers the following areas: • Ostomy care accessories market sizing • Ostomy care accessories market forecast • Ostomy care accessories market industry analysis Read the full report: https://www.reportlinker.com/p05048547/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.
Apple products and vacuums are already marked down.
Save on grill deals at the Black Friday 2020 sale, featuring gas grill, pellet grill & more BBQ grill discounts
(Bloomberg) -- U.S. stocks rallied toward records as the formal start of President-elect Joe Biden’s transition joined positive vaccine news and rising stimulus odds to spur more risk taking.The Dow Jones Industrial Average climbed within points of 30,000, led by a 5% rally in Boeing Co. The S&P 500 and Russell 2000 jumped, outpacing gains in the tech-heavy Nasdaq indexes as investors doubled down on economically sensitive sectors such as travel and energy. Haven assets were broadly weaker, while Bitcoin extended its searing rally, surpassing $19,000 for the first time since 2017.Stock markets globally trended higher after the General Services Administration acknowledged Biden as the apparent winner of the presidential election. The move reduces political uncertainty in the U.S., giving Biden and his team access to current agency officials, briefing books, some $6 million in funding and other resources. Markets also cheered his plan to nominate former Federal Reserve Chair Janet Yellen to lead the Treasury Department.“Markets love certainty and the move by Trump overnight partially removes ambiguity over the presidential succession,” Jeffrey Halley, a senior market analyst with Oanda Asia Pacific Pte, wrote in a note. “A Biden administration is expected to be much less isolationist, with hopes that the U.S. will reengage on global trade and improve relations with China.”Wall Street is also viewing a possible Yellen appointment as reason to count on more economic stimulus. She recently said the recovery will be uneven and lackluster if Congress doesn’t spend more to fight unemployment and keep small businesses afloat. That’s fueling the rotation out of defensive technology stocks and into assets that have been hardest hit by the pandemic, such as airlines and energy producers.In other markets, gold dropped to a four-month low and the dollar weakened against its major peers.In New Zealand, the government proposed adding home prices to the central bank’s remit to rein in an overheating property market. The move has prompted investors to reduce bets on lower interest rates, pushing the kiwi to the highest level since June 2018.In Germany, the operator of the DAX index announced the biggest overhaul since the index’s inception in 1988. The number of members will increase to 40 from 30 and new quality criteria will be imposed on both existing and prospective members.Here are some key events coming up:Minutes of the most recent Federal Open Market Committee meeting are due Wednesday.U.S. jobless claims, GDP and personal spending data come Wednesday.U.K. expected on Wednesday to deliver the government’s spending plans for next year.Thursday sees a policy decision and briefing from the Bank of Korea.U.S. celebrates the Thanksgiving holiday on Thursday.The week ends with Black Friday, the traditional start of the U.S. holiday shopping season.These are the main moves in markets:StocksThe S&P 500 Index rose 0.9% as of 10:29 a.m. New York time.The Stoxx Europe 600 Index rose 0.6%.The MSCI Asia Pacific Index rose 0.9%.The MSCI Emerging Market Index was little changed.CurrenciesThe Bloomberg Dollar Spot Index fell 0.2%.The euro climbed 0.2% to $1.187.The British pound gained 0.1% to $1.3333.The onshore yuan was little changed at 6.586 per dollar.The Japanese yen was little changed at 104.54 per dollar.BondsThe yield on 10-year Treasuries jumped two basis points to 0.87%.The yield on two-year Treasuries increased less than one basis point to 0.16%.Germany’s 10-year yield gained one basis point to -0.58%.Britain’s 10-year yield was unchanged at 0.318%.Japan’s 10-year yield climbed one basis point to 0.025%.CommoditiesWest Texas Intermediate crude increased 1.1% to $43.53 a barrel.Brent crude climbed 1.1% to $46.55 a barrel.Gold weakened 1.8% to $1,804.91 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
EA has outlined enhancements for 'FIFA 21' on PS5, including the use of the DualSense's triggers to reflect a player's fatigue.